Form 4: ANI Pharmaceuticals Executive Christopher Mutz Reports Stock Transaction
SEC Form 4 Filing
Christopher Mutz, Head of Rare Disease at ANI Pharmaceuticals, reports a transaction involving the withholding of shares for tax purposes related to vesting restricted stock.
Summary
- On February 28, 2025, Christopher Mutz, Head of Rare Disease at ANI Pharmaceuticals, reported a transaction on SEC Form 4.
- The transaction involved the withholding of 1,275 shares of common stock at a price of $61.89 for tax purposes.
- This was related to the vesting of 4,342 shares of restricted stock previously reported.
- Following the transaction, Mutz beneficially owns 114,191 shares of ANI Pharmaceuticals common stock.
Sentiment
Score: 5
Explanation: The document is a standard SEC filing reporting a routine transaction. It doesn't inherently convey positive or negative sentiment.
Industry Context
Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. This filing indicates activity related to vested stock awards.
Stakeholder Impact
- The transaction has a minimal direct impact on stakeholders, as it is a routine tax-related withholding of shares.
Key Dates
| Date | Description |
|---|---|
| 02/28/2025 | Date of the reported transaction (stock withholding for taxes). |
| 03/04/2025 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.